Septerna (NASDAQ:SEPN) Hits New 1-Year High on Analyst Upgrade

Septerna, Inc. (NASDAQ:SEPN) reached a new 52-week high during trading on Wednesday after Zacks Research upgraded the stock from a strong sell rating to a hold rating. The stock traded as high as $32.41 and last traded at $32.0660, with a volume of 116836 shares. The stock had previously closed at $30.86.

Several other equities research analysts also recently weighed in on SEPN. Raymond James Financial began coverage on Septerna in a report on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 price objective for the company. Wall Street Zen cut shares of Septerna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 10th. JonesTrading started coverage on shares of Septerna in a research report on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price objective on the stock. Truist Financial assumed coverage on Septerna in a research report on Monday, December 15th. They issued a “buy” rating and a $34.00 price target on the stock. Finally, Wells Fargo & Company raised shares of Septerna from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $18.00 to $28.00 in a research note on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $33.83.

Insider Buying and Selling

In other news, COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total value of $115,880.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at $5,046,834.73. The trade was a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Septerna

Several large investors have recently added to or reduced their stakes in SEPN. Woodline Partners LP grew its holdings in Septerna by 94.2% in the 1st quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after buying an additional 282,585 shares during the period. Rhumbline Advisers boosted its position in shares of Septerna by 16.6% in the first quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock worth $135,000 after acquiring an additional 3,323 shares during the last quarter. Geode Capital Management LLC grew its holdings in Septerna by 19.1% in the second quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after purchasing an additional 78,316 shares during the period. Intech Investment Management LLC acquired a new position in Septerna during the second quarter worth approximately $129,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its position in Septerna by 116.7% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 222,702 shares of the company’s stock worth $2,354,000 after purchasing an additional 119,953 shares during the last quarter.

Septerna Stock Performance

The stock’s fifty day simple moving average is $26.96 and its two-hundred day simple moving average is $22.15. The company has a market cap of $1.30 billion, a price-to-earnings ratio of -19.22 and a beta of 3.85.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.